AEON Biopharma (AEON) SC 13DAEON Biopharma / Strathspey Crown ownership change

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

____________________

SCHEDULE 13D

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

RULE 13d-2(a)

Under the Securities Exchange Act of 1934

(Amendment No. )*

Class A Common Stock, $0.0001 par value per share

(Title of Class of Securities)

00791X100

(CUSIP Number)

Strathspey Crown Holdings Group, LLC

4040 MacArthur Boulevard, Suite 210

Newport Beach, CA  92660

(949) 260-1700

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

July 21, 2023

(Date of Event Which Requires Filing of This Statement)

SECURITY AND ISSUER.

This Schedule 13D relates to shares of the Issuer’s Class A Common Stock. The Issuer’s principal executive office is located at 5 Park Plaza, Suite 1750, Irvine, California 92614.

Item 2.

IDENTITY AND BACKGROUND.

(a) This Schedule 13D is filed by the Reporting Person. 

(b) The business address of the Reporting Person is 4040 MacArthur Boulevard, Suite 210, Newport Beach, California 92660. 

(c) The Reporting Person is a physician-owned cooperative growth equity firm. 

(d) During the last five years, the Reporting Person has not been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors). 

(e) During the last five years, the Reporting Person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of which it was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. 

(f) The Reporting Person is a Delaware limited liability company.  

Item 3.

SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

All of the shares of Class A Common Stock beneficially owned by the Reporting Person were acquired pursuant to a business combination agreement, dated December 12, 2022 (the “Business Combination Agreement”), by and among Priveterra Acquisition Corp., a Delaware corporation (“Priveterra”), Priveterra Merger Sub, Inc., a wholly owned subsidiary of Priveterra (“Merger Sub”), and AEON Biopharma, Inc., a Delaware corporation (“Old AEON”). Pursuant to the Business Combination Agreement, on July 21, 2023 (the “Closing Date”), Merger Sub was merged with and into Old AEON, with Old AEON surviving the merger as a wholly owned subsidiary of Priveterra. Upon the closing of the merger, Priveterra changed its name to “AEON Biopharma, Inc.” (the “Business Combination” and, together with the other transactions contemplated by the Business Combination Agreement, the “Transactions”). The summary description in this Schedule 13D of the Business Combination Agreement and the Transactions effected thereby is qualified in its entirety by reference to the full text of the Business Combination Agreement and Amendment No. 1 to the Business Combination Agreement, copies which are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and incorporated herein by reference.

Item 4.

PURPOSE OF TRANSACTION.

The information reported in Item 3 of this Schedule 13D is incorporated by reference into this Item 4.

The Reporting Person plans to hold its shares of Class A Common Stock reported herein until distributed to its members in connection with a tender offer the Reporting Person currently expects to undertake subsequent to the date of this Schedule 13D, pursuant to which the Reporting Person shall repurchase certain of the membership interests of the Reporting Person held by its members in exchange for, among other consideration, certain of the Reporting Person’s shares of Class A Common Stock reported herein (the “Tender Offer Distribution”).

The Reporting Person may acquire additional shares of Class A Common Stock upon the achievement by the Issuer of certain milestones as described in the Business Combination Agreement (the “Earnout Shares”).

Except for the Tender Offer Distribution and the receipt of any Earnout Shares, the Reporting Person currently has no present plans or proposals which would be related to or would result in any of the matters described in Items 4(a)-(j) of the Instructions to Schedule 13D.

INTEREST IN SECURITIES OF THE COMPANY.

(a) See rows (11) and (13) of the cover page to this Schedule 13D for the aggregate number of shares of Class A Common Stock and the percentage of the shares of Class A Common Stock beneficially owned by the Reporting Person. The percentage used in this Schedule 13D is calculated based upon 37,154,198 shares of Class A Common Stock issued and outstanding as of July 27, 2023, as reported by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on July 27, 2023. 

(b) See rows (7) through (10) of the cover page to this Schedule 13D for the number of shares of Class A Common Stock as to which the Reporting Person has the sole or shared power to vote or direct the vote, and sole or shared power to dispose or director the disposition. 

(c) Except as set forth herein, no transactions in the shares of Class A Common Stock were effected by the Reporting Person during the past 60 days. 

(d) Except as set forth herein, to the knowledge of the Reporting Person, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any shares of Class A Common Stock beneficially owned by the Reporting Person. 

(e) Not applicable.

Item 6.

CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.

Registration Rights Agreement

On July 21, 2023, in connection with the consummation of the Business Combination and as contemplated by the Business Combination Agreement, the Issuer, Priveterra Sponsor, LLC, Alphaeon 1, LLC, Daewoong Co., LTD, Daewoong Pharmaceutical Co., Ltd., the Reporting Person, and certain other former stockholders of Old AEON entered into an amended and restated registration rights agreement (the “A&R Registration Rights Agreement”), pursuant to which each party thereto (other than the Issuer) was granted certain registration rights with respect to their respective shares of Class A Common Stock. The foregoing description is qualified in its entirety by the full text of the A&R Registration Rights Agreement, which is included as Exhibit 99.3 to this Schedule 13D and incorporated herein by reference.

Shares Subject to Lock-Up Provisions of the Issuer’s Amended and Restated Bylaws

The Reporting Person may not sell, assign, or transfer any of its Lock-Up Shares, subject to certain permitted transfers, until the earliest of (a) the one-year anniversary of the Closing Date, and (b) the date upon which there occurs the completion of a liquidation, merger, stock exchange, reorganization, or other similar transaction that results in all of the public stockholders of the Issuer having the right to exchange its Class A Common Stock for cash, securities, or other property, subject to certain conditions set forth in the A&R Bylaws. The foregoing description is qualified in its entirety by the full text of the A&R Bylaws, a copy of which is filed as Exhibit 3.2 to the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 27, 2023 and incorporated herein by reference.

Item 7.

MATERIAL TO BE FILED AS EXHIBITS.

STRATHSPEY CROWN HOLDINGS GROUP, LLC

By:

Name:

Andrew Lusk

Title:

Attorney-in-Fact for Robert E. Grant, Manager

of Strathspey Crown Holdings Group, LLC